Health
EU lawmakers vote to extend exclusivity period for new medicines
Lawmakers in an EU parliamentary committee voted on Tuesday to extend the exclusivity period for new medicines from the original draft, seeking to address concerns
French biotech company Valneva raises sales forecast for its products
French biotech company Valneva on Wednesday raised its product sales forecast and said it now expects revenue of 170 million to 190 million euros ($184.72
New Zealand government to ban disposable e-cigarettes
The New Zealand government said on Wednesday it would ban the sale of disposable e-cigarettes, increase fines for retailers selling them to under-18s and improve
US approves first gene therapy for children with rare genetic diseases
US health regulators on Monday approved a gene therapy from Britain’s Orchard Therapeutics to treat children with metachromatic leukodystrophy, making it the first US-approved treatment
UnitedHealth will pay more than $2 billion to health care providers
UnitedHealth Group said Monday that it has so far paid out more than $2 billion in upfront payments to help health care providers who have
U.S. Centers for Disease Control and Prevention urges measles vaccination
The US Centers for Disease Control and Prevention on Monday issued a public health advisory urging people, especially children and international travellers, to get vaccinated
U.S. agency calls for temporary payments to healthcare providers
The U.S. government said Friday it has called on states to make interim payments to healthcare providers affected by the cyberattack on UnitedHealth unit Health
Pfizer to cut stake in toothpaste maker Sensodyne Haleon to 24%
Consumer products company Haleon said on Monday that US drugmaker Pfizer, its major shareholder, will sell its stake in the company to about 24%.
Biden pushes for more women’s health research
President Joe Biden on Monday will issue an executive order expanding U.S. government research on women’s health and spend $200 million next year to better
Gilead CAR-T cancer treatment capacity to quadruple by 2026
Gilead Sciences will be able to quadruple its production of cancer cell therapies by 2026 thanks to improvements in US biotech manufacturing processes, the executive